Dongkook Pharmaceutical Co Stock EBITDA
| 086450 Stock | KRW 15,060 10.00 0.07% |
DongKook Pharmaceutical Co fundamentals help investors to digest information that contributes to DongKook Pharmaceutical's financial success or failures. It also enables traders to predict the movement of DongKook Stock. The fundamental analysis module provides a way to measure DongKook Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DongKook Pharmaceutical stock.
DongKook |
DongKook Pharmaceutical Co Company EBITDA Analysis
DongKook Pharmaceutical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current DongKook Pharmaceutical EBITDA | 83.48 B |
Most of DongKook Pharmaceutical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DongKook Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, DongKook Pharmaceutical Co reported earnings before interest,tax, depreciation and amortization of 83.48 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Republic of Korea stocks is notably lower than that of the firm.
DongKook EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DongKook Pharmaceutical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DongKook Pharmaceutical could also be used in its relative valuation, which is a method of valuing DongKook Pharmaceutical by comparing valuation metrics of similar companies.DongKook Pharmaceutical is currently under evaluation in ebitda category among its peers.
DongKook Fundamentals
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X | |||
| Revenue | 594.19 B | |||
| Gross Profit | 337.12 B | |||
| EBITDA | 83.48 B | |||
| Net Income | 52.92 B | |||
| Cash And Equivalents | 85.44 B | |||
| Total Debt | 13.69 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 2.61 X | |||
| Book Value Per Share | 23,358 X | |||
| Cash Flow From Operations | 44.65 B | |||
| Target Price | 22667.0 | |||
| Number Of Employees | 1.06 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 145.91 B | |||
| Total Asset | 750.08 B | |||
| Retained Earnings | 172.22 B | |||
| Working Capital | 139.53 B | |||
| Current Asset | 203.59 B | |||
| Current Liabilities | 64.06 B | |||
| Z Score | 6.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 750.08 B |
About DongKook Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DongKook Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.